Literature DB >> 10090449

Topical pefloxacin in bacterial keratitis.

R B Vajpayee1, N Sharma, B Verma, M Vajpayee, S K Gupta, G Satpathy, R Saxena.   

Abstract

PROBLEM: To evaluate the clinical efficacy and safety of topical pefloxacin 0.3% drops as the sole antibiotic used to treat culture positive bacterial corneal ulcers.
METHODS: Forty two consecutive Gram's smear-positive cases of bacterial corneal ulcers were enrolled for this prospective open labelled clinical trial. All patients underwent a complete clinical and microbiological work up and were put on topical 0.3% pefloxacin drops with supportive cycloplegic, vitamins and antiglaucoma therapy. Of 42 cases, 4 cases of mycotic keratitis and 6 culture negative cases were excluded from the study.
RESULTS: Positive microbiologic cultures were obtained in 84.2% (32 of 38) cases. Staphylococcus aureus (14/32; 43.7%) and coagulase negative Staphylococci (12/32; 37.5%) were the two most common organisms isolated. Resolution of the corneal ulcer was achieved in 31 out of 32 cases (96.9%) with a mean duration of 9.3+/-5.3 days (range 3-21 days). Best corrected visual acuity of 20/200 or better was achieved in 65.6% of cases at 4 weeks post resolution. Corneal deposits were observed in one case which disappeared 8 days following discontinuation of therapy.
CONCLUSIONS: Topical pefloxacin is effective as a single antibiotic agent for the treatment of bacterial keratitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10090449     DOI: 10.1023/a:1006153407141

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  12 in total

1.  Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.

Authors:  R A Hyndiuk; R A Eiferman; D R Caldwell; G O Rosenwasser; C I Santos; H R Katz; S S Badrinath; M K Reddy; J P Adenis; V Klauss
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

Review 2.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

3.  The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis.

Authors:  S D McLeod; A Kolahdouz-Isfahani; K Rostamian; C W Flowers; P P Lee; P J McDonnell
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

4.  Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis.

Authors:  D J Parks; D A Abrams; F A Sarfarazi; H R Katz
Journal:  Am J Ophthalmol       Date:  1993-04-15       Impact factor: 5.258

5.  Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.

Authors:  T P O'Brien; M G Maguire; N E Fink; E Alfonso; P McDonnell
Journal:  Arch Ophthalmol       Date:  1995-10

6.  In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.

Authors:  H C Neu; N X Chin; P Labthavikul; G Saha
Journal:  Chemioterapia       Date:  1984-08

7.  Empirical or culture-guided therapy for microbial keratitis? A plea for data.

Authors:  P J McDonnell
Journal:  Arch Ophthalmol       Date:  1996-01

8.  Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits.

Authors:  T P O'Brien; M R Sawusch; J D Dick; J D Gottsch
Journal:  Arch Ophthalmol       Date:  1988-10

9.  Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis.

Authors:  M Wolff; B Regnier; C Daldoss; M Nkam; F Vachon
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

10.  Spectrum of microbial keratitis in South Florida.

Authors:  T J Liesegang; R K Forster
Journal:  Am J Ophthalmol       Date:  1980-07       Impact factor: 5.258

View more
  1 in total

Review 1.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.